52730-46-8
Chemical Structure
(S)-Viloxazine
Synonym(s): (S)-Viloxazin; (S)-Emovit
- CAS. Nr.: 52730-46-8
- Formula:C13H19NO3
- Molecular Weight:237.29
InChIKey: YWPHCCPCQOJSGZ-NSHDSACASA-N
SMILES: CCOC1=C(OC[C@H]2OCCNC2)C=CC=C1
Biological Activity: (S)-Viloxazine ((S)-Viloxazin) is the more pharmacologically active isomer of Viloxazine (HY-W380450). (S)-Viloxazine is an orally active, blood-brain barrier penetrant norepinephrine transporter inhibitor. It also acts as a 5-HT2C receptor agonist and a 5-HT2B receptor inhibitor. (S)-Viloxazine modulates serotonergic and noradrenergic activities, blocks norepinephrine reuptake, and elevates extracellular levels of serotonin, norepinephrine and dopamine in the prefrontal cortex, without inhibiting 5-HT or dopamine uptake into synaptosomes. (S)-Viloxazine can be used in research related to attention deficit hyperactivity disorder and depression[1][2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(S)-Viloxazine | (S)-Viloxazine ((S)-Viloxazin) is the more pharmacologically active isomer of Viloxazine (HY-W380450). (S)-Viloxazine is an orally active, blood-brain barrier penetrant norepinephrine transporter inhibitor. It also acts as a 5-HT2C receptor agonist and a 5-HT2B receptor inhibitor. (S)-Viloxazine modulates serotonergic and noradrenergic activities, blocks norepinephrine reuptake, and elevates extracellular levels of serotonin, norepinephrine and dopamine in the prefrontal cortex, without inhibiting 5-HT or dopamine uptake into synaptosomes. (S)-Viloxazine can be used in research related to attention deficit hyperactivity disorder and depression. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yu C, et al. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. Journal of experimental pharmacology. 2020;12:285-300. [Content Brief]
- [2]. Edinoff AN, et al. Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder. Front Psychiatry. 2021 Dec 17;12:789982.
- [3]. Findling RL, et al. Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial. CNS drugs. 2025 Nov;39(11):1157-1172.
- [4]. Blackburn TP, et al. Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo. European journal of pharmacology. 1978 Dec 01;52(3-4):367-74.
